Lexicon Pharmaceuticals | LXRX - Capital Ordinário





Capital Ordinário Alterar Data
Abbott USD 1.74B 23.39B 2025-09
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
AstraZeneca USD 1.55B 73K 2026-03
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Halozyme Therapeutics USD 118.52M 741K 2026-03
Illumina USD 151.91M 893K 2026-03
Insmed USD 216.52M 2.27M 2026-03
Ironwood Pharmaceuticals USD 160K 0 2024-12
J&J USD 2.41B 1.74M 2025-12
Lexicon Pharmaceuticals USD 363.47M 67K 2025-12
MacroGenics USD 63.32M 60K 2025-12
MannKind USD 308.91M 1.07M 2026-03
Merck USD 2.47B 12.72M 2025-12
Moderna USD 391M 2M 2025-09
Novartis USD 1.91B 60K 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Sarepta Therapeutics USD 105.57M 607K 2026-03
Thermo Fisher Scientific USD 371.62M 4.09M 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
United Therapeutics USD 42.16M 1.49M 2026-03
Vanda Pharmaceuticals USD 58K 0 2024-12